{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:49:01Z","timestamp":1791895741699,"version":"4.3.4"},"reference-count":239,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1053\/j.jvca.2026.07.032","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:58:56Z","timestamp":1784534336000},"page":"3749-3771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Cardiovascular Pharmacotherapy. IX. Protection Against Major Adverse Cardiovascular Events by Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Obesity"],"prefix":"10.1053","volume":"40","author":[{"given":"Paul S.","family":"Pagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Freed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2026.07.032_bib0001","doi-asserted-by":"crossref","first-page":"238","DOI":"10.37765\/ajmc.2026.89920","article-title":"Medication use for patients with obesity: Trends and characteristics for US employees","volume":"32","author":"Good","year":"2026","journal-title":"Am J Manag Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0002","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1111\/dom.70555","article-title":"Sex-specific changes in GLP-1RA trends (2019-2024): Impact to FDA approval of semaglutide (Wegovy) for chronic weight management in the United States","volume":"28","author":"Daggolu","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-025-04528-7","article-title":"Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: A population study in Great Britain","volume":"24","author":"Jackson","year":"2026","journal-title":"BMC Medicine"},{"key":"10.1053\/j.jvca.2026.07.032_bib0004","first-page":"77724","article-title":"73 FR 77724 - Guidance for industry on diabetes mellitus-Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Office of the Federal Register, National Archives and Records Administration","volume":"73","year":"2008","journal-title":"Federal Register"},{"key":"10.1053\/j.jvca.2026.07.032_bib0005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bja.2025.04.001","article-title":"Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement","volume":"135","author":"Oprea","year":"2025","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2026.07.032_bib0006","doi-asserted-by":"crossref","first-page":"E550","DOI":"10.1152\/ajpendo.00326.2004","article-title":"Human duodenal enteroendocrine cells: Course of both incretin peptides, GLP-1 and GIP","volume":"290","author":"Theodorakis","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0007","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.jvca.2026.07.032_bib0008","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1053\/j.jvca.2026.07.032_bib0009","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.jvca.2026.07.032_bib0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","article-title":"Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut","volume":"211","author":"Holst","year":"1987","journal-title":"FEBS Lett"},{"key":"10.1053\/j.jvca.2026.07.032_bib0011","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1210\/jcem-24-10-1076","article-title":"Plasma insulin response to oral and intravenous glucose administration","volume":"24","author":"Elrick","year":"1964","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0012","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0013","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0014","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0015","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2337\/diacare.22.7.1137","article-title":"Continuous subcutaneous infusion of glucagon-like peptide lowers plasma glucose and reduces appetite in type 2 diabetic patients","volume":"22","author":"Toft-Nielsen","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0016","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s001250050664","article-title":"Near-normalisation of diural glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM","volume":"40","author":"Rachman","year":"1997","journal-title":"Diabetologia"},{"key":"10.1053\/j.jvca.2026.07.032_bib0017","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glyceamic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.032_bib0018","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenous administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2026.07.032_bib0019","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00125-005-1847-7","article-title":"Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetized pig","volume":"48","author":"Plamboeck","year":"2005","journal-title":"Diabetologia"},{"key":"10.1053\/j.jvca.2026.07.032_bib0020","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1053\/j.jvca.2026.07.032_bib0021","doi-asserted-by":"crossref","first-page":"20259","DOI":"10.1016\/S0021-9258(17)30498-2","article-title":"Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom","volume":"265","author":"Eng","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1053\/j.jvca.2026.07.032_bib0022","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1016\/S0021-9258(18)49932-2","volume":"266","author":"Raufman","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1053\/j.jvca.2026.07.032_bib0023","first-page":"147","article-title":"Exendin peptides","volume":"59","author":"Eng","year":"1992","journal-title":"Mt Sinai J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0024","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2337\/diacare.15.2.270","article-title":"Insulinotropic action of glucagonlike peptide-I-(3-37) in diabetic and nondiabetic subjects","volume":"15","author":"Nathan","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0025","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1210\/jc.2002-021545","article-title":"Synthetic exendin-4 (exentide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes","volume":"88","author":"Kolterman","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0026","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0027","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0028","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2415550121","article-title":"The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity","volume":"121","author":"Friedman","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.jvca.2026.07.032_bib0029","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"10.1053\/j.jvca.2026.07.032_bib0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1053\/j.jvca.2026.07.032_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108045","article-title":"History of glucagon-like peptide-1 receptor agonists","volume":"222","author":"Darwish","year":"2025","journal-title":"Pharmacol Res"},{"key":"10.1053\/j.jvca.2026.07.032_bib0032","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): A multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0034","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2337\/dc09-1914","article-title":"DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.032_bib0036","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2026.07.032_bib0037","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN-3): A 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0038","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0039","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel duel GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.032_bib0040","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0041","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2026.07.032_bib0042","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0043","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0044","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0045","article-title":"Keytruda hangs on to best-seller crown as GLP-1s gain ground","author":"Manalac","year":"2026","journal-title":"BioSpace"},{"key":"10.1053\/j.jvca.2026.07.032_bib0046","series-title":"Outlook for obesity in 2026: From consolidation and acceleration","author":"Meadowcroft","year":"2026"},{"key":"10.1053\/j.jvca.2026.07.032_bib0047","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","article-title":"Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury","volume":"54","author":"Bose","year":"2005","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2026.07.032_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130894","article-title":"Cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart","volume":"10","author":"Aravindhan","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.07.032_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023570","article-title":"Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia\/reperfusion injury: Evidence for improving cardiac metabolic efficiency","volume":"6","author":"Bao","year":"2011","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.07.032_bib0050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-014-0132-9","article-title":"Exendin-4 ameliorates cardiac ischemia\/reperfusion injury via caveolae and caveolins-3","volume":"13","author":"Tsutsumi","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0051","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","article-title":"Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury","volume":"53","author":"Timmers","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0052","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/db08-1193","article-title":"GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice","volume":"58","author":"Noyan-Ashraf","year":"2009","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2026.07.032_bib0053","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated by both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.032_bib0054","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","article-title":"Effects of glucacon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion","volume":"109","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.032_bib0055","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"Lonborg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0056","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/ATVBAHA.113.301586","article-title":"Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of exenatide myocardial protection in revascularization study","volume":"33","author":"Woo","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0057","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.amjcard.2007.05.022","article-title":"Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting","volume":"100","author":"Sokos","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0058","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/db13-1849","article-title":"Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: Results from a randomized study","volume":"63","author":"Lonborg","year":"2014","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2026.07.032_bib0059","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2026.07.032_bib0060","doi-asserted-by":"crossref","first-page":"E1209","DOI":"10.1152\/ajpendo.00237.2004","article-title":"Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease","volume":"287","author":"Nystrom","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0061","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0062","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1161\/CIRCULATIONAHA.113.006985","article-title":"Glucagon-like peptide-1 receptor agonists for diabetes mellitus. A role in cardiovascular disease","volume":"129","author":"Smilowitz","year":"2014","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.032_bib0063","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-014-0142-7","article-title":"Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists","volume":"13","author":"Saraiva","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0064","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ahj.2015.02.002","article-title":"Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo","volume":"169","author":"Bentley-Lewis","year":"2015","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0065","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0066","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: An exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0067","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004743","article-title":"Role of B-type natriuretic peptide and N-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus","volume":"6","author":"Wolsk","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2026.07.032_bib0068","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021327","article-title":"Risk estimates of imminent cardiovascular death and heart failure hospitalization are improved using serial natriuretic peptide measurements in patients with coronary artery disease and type 2 diabetes","volume":"11","author":"Wolsk","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2026.07.032_bib0069","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/dom.14954","article-title":"Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial","volume":"25","author":"Gerstein","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0070","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1631263","article-title":"Retinopathy, nephropathy, and subsequent cardiovascular events in patients with type 2 diabetes and acute coronary syndrome in the ELIXA: The important of disease duration","volume":"2018","author":"Seferovic","year":"2018","journal-title":"J Diabetes Res"},{"key":"10.1053\/j.jvca.2026.07.032_bib0071","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12933-020-01150-0","article-title":"Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial","volume":"19","author":"Wijkman","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0072","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ahj.2013.07.012","article-title":"Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial","volume":"166","author":"Marso","year":"2013","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0073","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0074","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0075","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","article-title":"Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"138","author":"Mann","year":"2018","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.032_bib0076","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.amjcard.2018.02.030","article-title":"Myocardial infarction subtypes in patients with type 2 diabetes mellitus and the effect of liraglutide therapy (from the LEADER trial)","volume":"121","author":"Marso","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0077","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1479164118783935","article-title":"Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial","volume":"15","author":"Nauck","year":"2018","journal-title":"Diab Vasc Dis Res"},{"key":"10.1053\/j.jvca.2026.07.032_bib0078","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.118.034516","article-title":"Effect of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without a history of myocardial infarction or stroke","volume":"138","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.032_bib0079","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1161\/CIRCULATIONAHA.118.033898","article-title":"Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: Results of the LEADER trial","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.032_bib0080","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jamacardio.2019.3080","article-title":"Occurrence of first and recurrent major adverse cardiovascular events with liraglutide treatment among patients with type 2 diabetes and high risk of cardiovascular events: A post hoc analysis of a randomized controlled trial","volume":"4","author":"Verma","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0081","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2337\/dc19-2251","article-title":"Cardiovascular risk reduction with liraglutide: An exploratory mediation analysis of the LEADER trial","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0082","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7326\/M18-1569","article-title":"Effect of liraglutide on cardiovascular outcomes in elderly patients: A post hoc analysis of a randomized clinical trial","volume":"170","author":"Gilbert","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0083","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1111\/dom.14126","article-title":"Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial","volume":"22","author":"Mosenzon","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0084","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2215\/CJN.11881019","article-title":"Safety of liraglutide in type 2 diabetes and chronic kidney disease","volume":"15","author":"Mann","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0085","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/dom.13826","article-title":"Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial","volume":"21","author":"Tack","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0086","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.2337\/dc20-0437","article-title":"Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: Post hoc analyses of the LEADER trial","volume":"43","author":"Crowley","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0087","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc17-2677","article-title":"Hypoglycemia, cardiovascular outcomes, and death: The LEADER experience","volume":"41","author":"Zinman","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0088","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/dc18-1094","article-title":"The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial","volume":"41","author":"Dhatariya","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0089","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","article-title":"Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol","volume":"37","author":"Laaksonen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0090","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-021-00536-1","article-title":"Ceramides and other sphingolipids as drivers of cardiovascular disease","volume":"18","author":"Choi","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0091","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41467-022-28496-1","article-title":"Dihydroceramide- and ceramide-profiling provides insights into human cardiometabolic disease etiology","volume":"13","author":"Wittenbecher","year":"2022","journal-title":"Nat Commun"},{"key":"10.1053\/j.jvca.2026.07.032_bib0092","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12933-023-01845-0","article-title":"Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes","volume":"22","author":"Denimal","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0093","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"10.1053\/j.jvca.2026.07.032_bib0094","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0095","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/bmj.290.6471.811","article-title":"Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: The Oslo study","volume":"290","author":"Dahl-Jorgensen","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1053\/j.jvca.2026.07.032_bib0096","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/14740338.2020.1772230","article-title":"Safety of injectable semaglutide for type 2 diabetes","volume":"19","author":"Peter","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1053\/j.jvca.2026.07.032_bib0097","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-019-0871-8","article-title":"Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: A post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial","volume":"18","author":"Leiter","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0098","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/dom.14941","article-title":"Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial","volume":"25","author":"Kolkailah","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0099","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/13696998.2023.2240957","article-title":"Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide","volume":"26","author":"Berry","year":"2023","journal-title":"J Med Econ"},{"key":"10.1053\/j.jvca.2026.07.032_bib0100","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.ekir.2024.04.028","article-title":"Effects of once-weekly semaglutide on kidney disease outcomes by KDIGO risk category in the SUSTAIN 6 trial","volume":"9","author":"Tuttle","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1053\/j.jvca.2026.07.032_bib0101","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1111\/dom.15860","article-title":"Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial","volume":"26","author":"Wang","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0102","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(20)30313-2","article-title":"Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: A post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials","volume":"8","author":"Mann","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0103","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/dom.13698","article-title":"Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials","volume":"21","author":"Verma","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0104","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/dom.14079","article-title":"The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials","volume":"22","author":"Leiter","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0105","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1111\/dom.14140","article-title":"Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0106","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/dom.14700","article-title":"Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease","volume":"24","author":"Verma","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0107","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1111\/dom.14160","article-title":"Effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0108","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: Pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.032_bib0109","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/dom.14578","article-title":"The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials","volume":"24","author":"Zobel","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0110","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s12933-025-03007-w","article-title":"Temporal and subgroup disparities in mediation effects of cardiovascular outcomes with liraglutide and semaglutide: A post-hoc analysis of LEADER and SUSTAIN-6 trials","volume":"24","author":"Peng","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0111","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0112","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/dom.13553","article-title":"Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0113","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0114","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1053\/j.jvca.2025.05.010","article-title":"Advances in cardiovascular pharmacotherapy. III. Sodium-glucose cotransporter type 2 inhibitors, part 1: Efficacy in heart failure and myocardial infarction","volume":"39","author":"Pagel","year":"2025","journal-title":"J Cardiothoracic Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.07.032_bib0115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.13955","article-title":"Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk","volume":"22","author":"Husain","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0116","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/STROKEAHA.121.037775","article-title":"Effects of semaglutide on stroke subtypes in Type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6","volume":"53","author":"Strain","year":"2022","journal-title":"Stroke"},{"key":"10.1053\/j.jvca.2026.07.032_bib0117","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/dom.14360","article-title":"Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide","volume":"23","author":"Verma","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0118","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13300-024-01659-7","article-title":"Cardiovascular, metabolic, and safety outcomes with semaglutide by baseline age: Post hoc analysis of SUSTAIN 6 and PIONEER 6","volume":"16","author":"Bain","year":"2025","journal-title":"Diabetes Ther"},{"key":"10.1053\/j.jvca.2026.07.032_bib0119","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1111\/dom.16621","article-title":"Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6","volume":"27","author":"Zhou","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12933-022-01489-6","article-title":"Semaglutide reduces cardiovascular events regardless of metformin use: A post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6","volume":"21","author":"Husain","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0121","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12933-023-01949-7","article-title":"Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","volume":"22","author":"Rossing","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0122","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/eurheartj\/ehae028","article-title":"Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: The SUSTAIN 6 and PIONEER 6 trials","volume":"45","author":"Mellbin","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0123","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1111\/dom.15081","article-title":"Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analysis of the SUSTAIN 6 and PIONEER 6 trials","volume":"25","author":"Verma","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0124","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2337\/dc21-1138","article-title":"Estimated life-years gained free of new or recurrent major cardiovascular events with the addition of semaglutide to standard of care in people with type 2 diabetes and high cardiovascular risk","volume":"45","author":"Westerlink","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0125","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int"},{"key":"10.1053\/j.jvca.2026.07.032_bib0126","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/ndt\/gfae150","article-title":"Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6","volume":"40","author":"Apperloo","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jvca.2026.07.032_bib0127","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.ekir.2022.07.167","article-title":"Hemoglobin A1c reduction with the GLP-1 receptor agonist semaglutide is independent of baseline eGFR: Post hoc analysis of the SUSTAIN and PIONEER programs","volume":"7","author":"Cherney","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1053\/j.jvca.2026.07.032_bib0128","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12933-022-01585-7","article-title":"Impact of semaglutide on high-sensitivity C-reactive protein: Exploratory patient-level analysis of SUSTAIN and PIONEER randomized clinical trials","volume":"21","author":"Mosenzon","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0129","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1080\/00325481.2022.2090794","article-title":"Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: Cost per outcome analysis of SUSTAIN-6 and PIONEER-6","volume":"134","author":"Hammerman","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0130","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/dom.15058","article-title":"Effects of oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial","volume":"25","author":"McGuire","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0131","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0132","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10741-025-10579-y","article-title":"The impact of oral semaglutide on cardiovascular events in patients with type 2 diabetes: Review of results from the SOUL trial","volume":"31","author":"Lehenbauer","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1053\/j.jvca.2026.07.032_bib0133","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","article-title":"Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: Prespecified analysis of the SOUL randomized trial","volume":"151","author":"Marx","year":"2025","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.032_bib0134","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2337\/dc25-1080","article-title":"Impact of oral semaglutide on kidney outcomes in people with type 2 diabetes: Results from the SOUL randomized trial","volume":"49","author":"Mann","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0135","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamainternmed.2025.7774","article-title":"Oral semaglutide and heart failure outcomes in persons with type 2 diabetes: A secondary analysis of the SOUL randomized clinical trial","volume":"186","author":"Pop-Busui","year":"2026","journal-title":"JAMA Intern Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0136","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamacardio.2026.0245","article-title":"Oral semaglutide and change in cardiovascular risk factors in high-risk type 2 diabetes: A post hoc secondary analysis of the SOUL randomized clinical trial","volume":"11","author":"Mulvagh","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0137","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jvca.2026.07.032_bib0138","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ehjcvp\/pvad080","article-title":"FLOW trial stopped early due to evidence of renal protection with semaglutide","volume":"10","author":"Gragnano","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1053\/j.jvca.2026.07.032_bib0139","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0140","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2215\/CJN.0000000974","article-title":"Kidney and survival outcomes with semaglutide by CKD severity in the FLOW trial","volume":"21","author":"Tuttle","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0141","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0142","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.2337\/dc25-0472","article-title":"Effects of semaglutide with or without concomitant mineralocorticoid receptor antagonist use in participants with type 2 diabetes and chronic kidney disease: A FLOW trial prespecified secondary analysis","volume":"48","author":"Rossing","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0143","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/eurheartj\/ehae613","article-title":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: The FLOW trial","volume":"46","author":"Mahaffey","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0144","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0145","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1093\/ndt\/gfaf114","article-title":"Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"40","author":"Cherney","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jvca.2026.07.032_bib0146","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.kint.2025.10.005","article-title":"REMODELing mechanistic trials for kidney disease: A multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide","volume":"109","author":"Pruijm","year":"2026","journal-title":"Kidney Int"},{"key":"10.1053\/j.jvca.2026.07.032_bib0147","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ehjcvp\/pvae071","article-title":"Design and baseline characteristics of the STRIDE trial: Evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes","volume":"10","author":"Bonaca","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1053\/j.jvca.2026.07.032_bib0148","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): A phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.032_bib0149","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1161\/CIR.0b013e318276fbcb","article-title":"Measurement and interpretation of the ankle-brachial index: A scientific statement from the American Heart Association","volume":"126","author":"Aboyans","year":"2012","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.032_bib0150","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/S0140-6736(25)00574-4","article-title":"Increasing walking capacity in patients with peripheral artery disease","volume":"405","author":"Beckman","year":"2025","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.032_bib0151","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cmet.2025.05.001","article-title":"GLP-1 RAs for peripheral artery disease: A remarkable STRIDE in the right direction","volume":"37","author":"Verma","year":"2025","journal-title":"Cell Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0152","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2337\/dc25-1082","article-title":"Benefit of semaglutide in symptomatic peripheral artery disease by baseline type 2 diabetes characteristics: Insights from STRIDE, a randomized, placebo-controlled, double-blind trial","volume":"48","author":"Rasouli","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0153","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.jacc.2025.08.046","article-title":"Sex differences in effectiveness of semaglutide in patients with peripheral artery disease: The STRIDE trial","volume":"86","author":"Verma","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0154","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2025.10.080","article-title":"Improvement in walking distance with semaglutide in smokers with peripheral artery disease: STRIDE trial subgroup analysis","volume":"87","author":"Sourij","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0155","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1093\/eurheartj\/ehag129","article-title":"Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: The STRIDE trial","volume":"47","author":"Nordanstig","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0156","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ahj.2015.12.009","article-title":"Rational and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial","volume":"174","author":"Holman","year":"2016","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2017.02.005","article-title":"Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)","volume":"187","author":"Mentz","year":"2017","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0158","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0159","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","article-title":"Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: A non-inferiority randomized controlled trial","volume":"28","author":"Ruff","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0160","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009304","article-title":"Effect of once-weekly exenatide on clinical outcomes according to baseline risk in patients with type 2 diabetes mellitus: Insights from the EXSCEL trial","volume":"7","author":"Mentz","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2026.07.032_bib0161","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12933-022-01555-z","article-title":"Effect of race on cardiometabolic responses to once-weekly exenatide: Insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)","volume":"21","author":"Davis","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0162","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/dom.14993","article-title":"Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)","volume":"25","author":"Green","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0163","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ejhf.3478","article-title":"Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial","volume":"27","author":"Neves","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.032_bib0164","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/dom.14313","article-title":"Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials","volume":"23","author":"Clegg","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111685","article-title":"Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL","volume":"212","author":"Gooding","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1053\/j.jvca.2026.07.032_bib0166","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ahj.2021.03.013","article-title":"Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus","volume":"239","author":"Barbery","year":"2021","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0167","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008018","article-title":"Clinical outcomes in patients with type 2 diabetes mellitus and peripheral artery disease: Results from the EXSCEL trial","volume":"12","author":"Badjatiya","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1053\/j.jvca.2026.07.032_bib0168","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14552","article-title":"Predicting major adverse limb events in individuals with type 2 diabetes: insights from the EXSCEL trial","volume":"38","author":"Weissler","year":"2021","journal-title":"Diabet Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0169","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.119.041659","article-title":"Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with or without heart failure and heart failure-related outcomes: Insights from the EXSCEL trial","volume":"140","author":"Fudim","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.032_bib0170","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2337\/dc19-1079","article-title":"Confirming the bidirectional nature of the association between severe hypoglycemic and cardiovascular events in type 2 diabetes: Insights from EXSCEL","volume":"43","author":"Standl","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0171","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/dc19-1065","article-title":"Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: Insights from the EXSCEL trial","volume":"43","author":"Bethel","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0172","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1111\/dom.14175","article-title":"Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial","volume":"22","author":"van der Aart-van der Beek","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0173","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-019-0942-x","article-title":"Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: Insights from the EXSCEL trial","volume":"18","author":"Clegg","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0174","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: Current advancements & challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1053\/j.jvca.2026.07.032_bib0175","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/dom.14223","article-title":"Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist","volume":"23","author":"Gerstein","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0176","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0177","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.122.063716","article-title":"Exploring the relationship between efpeglenatide dose and cardiovascular outcomes in type 2 diabetes: Insights from the AMPLITUDE-O trial","volume":"147","author":"Gerstein","year":"2023","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.032_bib0178","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/CIRCULATIONAHA.121.057934","article-title":"Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: Exploratory analysis of the AMPLITUDE-O trial","volume":"145","author":"Lam","year":"2022","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.032_bib0179","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","article-title":"GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes","volume":"82","author":"Neves","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0180","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/dom.15417","article-title":"Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial","volume":"26","author":"Gerstein","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0181","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12933-024-02432-7","article-title":"Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: A participant-level exploratory analysis of the AMPLITUDE-O trial","volume":"23","author":"Del Prato","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0182","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2018.03.030","article-title":"Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics","volume":"203","author":"Green","year":"2018","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0183","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.032_bib0184","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(18)32348-1","article-title":"HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?","volume":"392","author":"Mafham","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.032_bib0185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ehjcvp\/pvae006","article-title":"Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial","volume":"10","author":"Krychtiuk","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1053\/j.jvca.2026.07.032_bib0186","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/ejhf.2660","article-title":"Albiglutide in patients with type 2 diabetes and heart failure: A post-hoc analysis from Harmony Outcomes","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.032_bib0187","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/dom.15479","article-title":"Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial","volume":"26","author":"Gilbert","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0188","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/eurjpc\/zwae379","article-title":"Albiglutide and atrial fibrillation in patients with type 2 diabetes and established cardiovascular disease: Insights from the Harmony Outcomes trial","volume":"33","author":"Krychtiuk","year":"2026","journal-title":"Eur J Prev Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0189","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","article-title":"GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes","volume":"82","author":"Neves","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0190","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/dom.13028","article-title":"Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide","volume":"20","author":"Gerstein","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0191","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.032_bib0192","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.032_bib0193","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1210\/clinem\/dgab065","article-title":"Efficacy and safety of dulaglutide in older patients: A post hoc analysis of the REWIND trial","volume":"106","author":"Riddle","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0194","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/dom.14760","article-title":"Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial","volume":"24","author":"Franek","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0195","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehaa777","article-title":"Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin","volume":"42","author":"Ferrannini","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0196","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12933-020-01179-1","article-title":"Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trial: A post hoc analysis","volume":"19","author":"Dagenais","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0197","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/dom.14634","article-title":"Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial","volume":"24","author":"Raubenheimer","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0198","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.259","article-title":"A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease","volume":"4","author":"Evans","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1053\/j.jvca.2026.07.032_bib0199","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(19)30423-1","article-title":"The effect of dulaglutide on stroke: An exploratory analysis of the REWIND trial","volume":"8","author":"Gerstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0200","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: An exploratory analysis of the REWIND trial","volume":"19","author":"Cukierman-Yaffe","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0201","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2337\/dc23-0231","article-title":"Dulaglutide and kidney function-related outcomes in type 2 diabetes: A REWIND post hoc analysis","volume":"46","author":"Botros","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0202","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12933-021-01386-4","article-title":"Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND","volume":"20","author":"Konig","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0203","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2337\/dc21-1160","article-title":"HbA1c reduction in dulaglutide-treated patients irrespective of duration of diabetes, microvascular disease, and BMI: A post hoc analysis from the REWIND trial","volume":"45","author":"Kwan","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0204","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ejhf.2670","article-title":"Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: A post-hoc analysis from the REWIND randomized trial","volume":"24","author":"Branch","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.032_bib0205","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2337\/dc22-2397","article-title":"Biomarker changes associated with both dulaglutide and cardiovascular events in the REWIND randomized controlled trial: A nested case-control post hoc analysis","volume":"46","author":"Gerstein","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0206","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0207","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0208","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.032_bib0209","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12020-024-03896-z","article-title":"Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial","volume":"86","author":"Qin","year":"2024","journal-title":"Endocrine"},{"key":"10.1053\/j.jvca.2026.07.032_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0211","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0212","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s13300-025-01784-x","article-title":"Can dual incretin receptor agonists exert better cardiovascular protection than selective GLP-1 receptor agonists? Highlights from SURPASS-CVOT","volume":"16","author":"Fadini","year":"2025","journal-title":"Diabetes Ther"},{"key":"10.1053\/j.jvca.2026.07.032_bib0213","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s13300-025-01829-1","article-title":"Rewriting diabetes therapy: How incretin modulation is transforming cardiovascular and renal outcomes","volume":"17","author":"Miramontes-Gonzalez","year":"2026","journal-title":"Diabetes Ther"},{"key":"10.1053\/j.jvca.2026.07.032_bib0214","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.pcad.2025.08.009","article-title":"Generalizability of SURPASS-CVOT to the United States: A nationally representative study","volume":"92","author":"Aggarwal","year":"2025","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1053\/j.jvca.2026.07.032_bib0215","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41591-025-04102-x","article-title":"Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice","volume":"32","author":"Kruger","year":"2026","journal-title":"Nat Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0216","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-026-03140-0","article-title":"CVOT Summit Report 2025: Advances along the cardiovascular-kidney-metabolic disease continuum","volume":"25","author":"Schnell","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0217","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S2213-8587(26)00032-X","article-title":"A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: Pre-specified exploratory analysis of the SURPASS-CVOT trial","volume":"14","author":"Zoungas","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0218","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide effects on cardiovascular outcomes in patients with overweight or obesity (SELECT) rationale and design","volume":"229","author":"Ryan","year":"2020","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0219","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/oby.23621","article-title":"Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics","volume":"31","author":"Lingvay","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.jvca.2026.07.032_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.102060","article-title":"Obesity, cardiovascular disease, and the promising role of semaglutide: Insights from the SELECT trial","volume":"49","author":"Irfan","year":"2024","journal-title":"Curr Prob Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0221","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0222","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/oby.24222","article-title":"Safety profile of semaglutide versus placebo in the SELECT study: A randomized controlled trial","volume":"33","author":"Kushner","year":"2025","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.jvca.2026.07.032_bib0223","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.jacc.2024.08.022","article-title":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT): Outcomes by sex","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0224","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jacc.2024.11.008","article-title":"Semaglutide improves cardiovascular outcomes in patients with history of coronary artery bypass graft and obesity","volume":"85","author":"Verma","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0225","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-026-04281-1","article-title":"Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: A prespecified analysis of the SELECT randomized trial","volume":"32","author":"Meyhofer","year":"2026","journal-title":"Nat Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0226","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2337\/dc24-0764","article-title":"Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT","volume":"47","author":"Lingvay","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.032_bib0227","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: A prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.032_bib0228","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: A prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.032_bib0229","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2024.06.026","article-title":"Should the SELECT trial make us comfortable using GLP-1 receptor agonists in HFrEF?","volume":"84","author":"Neves","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0230","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jamacardio.2025.4824","article-title":"Semaglutide and hospitalizations in patients with obesity and established cardiovascular disease: An exploratory analysis of the SELECT randomized clinical trial","volume":"11","author":"Nicholls","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0231","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0232","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ahj.2024.05.007","article-title":"Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial","volume":"276","author":"Lusk","year":"2024","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2026.07.032_bib0233","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/oby.24332","article-title":"Tirzepatide for reduction of morbidity and mortality in adults with obesity: Rationale and design of the SURMOUNT-MMO trial","volume":"33","author":"Lam","year":"2025","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.jvca.2026.07.032_bib0234","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41591-025-04071-1","article-title":"Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: Secondary outcomes of the SURMOUNT-OSA randomized trial","volume":"32","author":"Malhotra","year":"2026","journal-title":"Nat Med"},{"key":"10.1053\/j.jvca.2026.07.032_bib0235","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0236","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0237","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0238","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: A meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2026.07.032_bib0239","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: A systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077026006142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077026006142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:04:25Z","timestamp":1791893065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077026006142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":239,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1053077026006142"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2026.07.032","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Cardiovascular Pharmacotherapy. IX. Protection Against Major Adverse Cardiovascular Events by Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Obesity","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2026.07.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}